Tradestie Institutional Equity Comparison Engine

CNTB vs ANRO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CNTB Overall Edge

CNTB Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Connect Biopharma Holdings Limited Ordinary Shares (CNTB) driven by superior Valuation, Options & Structure while ANRO counters with relative strength in Growth & Margin, Momentum & Technical. Fundamentally, CNTB trades at 0.8x Forward P/E with -2384.5% operating margin (+5666.7% YoY revenue) versus ANRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CNTB sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against ANRO sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CNTB
CNTB 0.8x vs ANRO N/M Fwd P/E
Growth & Margin Winner ANRO
Op Margin -2384.5% vs 0.0% ยท YoY +5666.7% vs +0.0%
Momentum & Technical Winner ANRO
1Y -72.1% vs +107.4% ยท 52W Pos 1% vs 54%
Options & Structure Winner CNTB
UNCLASSIFIED (100th %ile IV) vs BREAKDOWN (8th %ile IV)
CNTB NASDAQ
Connect Biopharma Holdings Limited Ordinary Shares
Pharmaceutical Preparations
$0.59
-7.94% 1D
Market Cap $42.6M
1M Return -34.21%
1Y Return -72.08%
Forward P/E 0.8x
Unified AI Score
41.0 / 100 SELL
Tech 25.0 Fund 48.0 Flow 66.0 Mom 55.0
ANRO NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$25.12
-7.37% 1D
Market Cap $1.2B
1M Return +10.08%
1Y Return +107.43%
Forward P/E N/M
Unified AI Score
34.3 / 100 SELL
Tech 15.0 Fund 38.0 Flow 64.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CNTB -72.08% ANRO +107.43% Spread: +179.51 pp (ANRO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CNTB TTM Op. Margin: -2384.5% ANRO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CNTB vs ANRO. Trailing 12-month operating profitability (CNTB -2384.5% vs ANRO 0.0%) and valuation multiples (CNTB 0.8x vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CNTB (5) vs ANRO (4)
Institutional Metric CNTB ANRO Criterion Row Winner
Market Capitalization Scale $42.6M $1.2B Larger Scale ANRO
Trailing P/E Ratio Valuation 0.8x N/M Lower Multiple CNTB
Forward P/E Ratio Valuation 0.8x N/M Lower Multiple CNTB
Revenue Growth (YoY) Growth +5666.7% +0.0% Higher Growth CNTB
Operating Margin (TTM) Profitability -2384.5% 0.0% Higher Margin ANRO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -140.5% -46.7% Higher ROE ANRO
52-Week Range Position Momentum 1% ($1โ€“$4) 54% ($11โ€“$37) Stronger Trend ANRO
Beta / 30D Volatility Risk Regime 0.92ฮฒ ยท 68% Vol 2.03ฮฒ ยท 94% Vol Lower Realized Risk CNTB
Unified Institutional Score Composite Signal 41.0 / 100 (SELL) 34.3 / 100 (SELL) Higher Composite CNTB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CNTB vs ANRO Buy Guide
CNTB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live CNTB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ANRO BREAKDOWN
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live ANRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CNTB nor ANRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.